according to plan. Management Discussion and Analysis of Business Operation for 1Q/2018 Bangchak Corporation Plc. I 5 Statement of Income Consolidated Statement of Income Q1/2017 Q4/2017 Q1/2018 YoY QoQ
fee (5,962,911.52) (9,396,413.79) (2,079,740.23) (3,633,085.03) 916,072,182.88 1,076,456,480.14 332,869,252.42 422,815,907.62 Unit: Baht Consolidated financial statements Separate financial statements
corporate income tax expense in the amount of THB 136 million. Management Discussion and Analysis of Business Operation for 3Q/2018 Bangchak Corporation Plc. I 5 Statement of Income Consolidated Statement of
for all domestic retail properties stood at 93%. Central Pattana Public Company Limited Management’s Discussion and Analysis (MD&A) Consolidated Financial Results: 2019 Major Events Performance Business
Discussion and Analysis (MD&A) Consolidated Financial Results: 1Q20 Major Events Performance Business Plan Document Quick Link Central Pattana Public Company Limited Management’s Discussion and Analysis (MD&A
borrowings 3,900 Repayment of LT borrowings 9,189 Cash paid for acquire net asset from business acquisition 22 Payment of other LT investments 8 Cash increase 2,226 Total 64,205 Total 64,205 7 3Q19 MD&A
Baht 135.00 million with 7UP’s total assets as per the consolidated financial statements for the period ending December 31, 2018. In addition, considering asset acquisition transactions for the past 6
consideration of Baht 135.00 million with 7UP’s total assets as per the consolidated financial statements for the period ending December 31, 2018. In addition, considering asset acquisition transactions for the
consideration of Baht 135.00 million with 7UP’s total assets as per the consolidated financial statements for the period ending December 31, 2018. In addition, considering asset acquisition transactions for the
borrowings 3,900 Repayment of LT borrowings 9,189 Cash paid for acquire net asset from business acquisition 22 Payment of other LT investments 8 Cash increase 2,226 Total 64,205 Total 64,205 7 3Q19 MD&A